Latitude Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Latitude Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,658	Closed	-$340K	–	159
2022 Q1	$340K	Buy	+4,658	New	+$313K	0.08%	237

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Latitude Advisors's BMY Position: Q2 2022 in Review

Latitude Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2022, closing a stake of 4,658 shares — an estimated $340K sold.

Latitude Advisors first reported a position in BMY in Q1 2022 and held it in 1 quarter. The position peaked at $340K in Q1 2022. 2,538 funds tracked by Wall St. Rank hold BMY as of Q2 2022.

Latitude Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2022 after selling out during the quarter.
Latitude Advisors sold 4,658 Bristol-Myers Squibb shares in Q2 2022, an estimated $340K.
Latitude Advisors first reported a position in Bristol-Myers Squibb in Q1 2022 and held it in 1 quarter.
Latitude Advisors's Bristol-Myers Squibb position peaked at $340K in Q1 2022.
2,538 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2022.

Based on Latitude Advisors's 13F filing for Q2 2022, filed 28 Jul 2022.